Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > CCR5


Brief Information

Name:C-C chemokine receptor type 5
Target Synonym:CCR-5,Chemokine (C-C Motif) Receptor 5 (Gene/Pseudogene),C-C Motif Chemokine Receptor 5 A159A,Chemokine Recptor CCR5 Delta32,C-C Chemokine Receptor Type 5,Chemokine Receptor CCR5,CD195 Antigen,C-C CKR-5,CCCKR5,IDDM22,CKR-5,CKR5,Receptors, CCR5,C-C Motif Chemokine Receptor 5,CD195,CHEMR13,CCR5,HIV-1 fusion coreceptor,C-C Motif Chemokine Receptor 5 (Gene/Pseudogene),Chemokine (C-C Motif) Receptor 5,CC-CKR-5,CMKBR5
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:12
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CHEK-ATP043-Cell-based assay

FACS assay shows that Anti-CCR5 antibody can bind to HEK293/Human CCR5 Stable Cell Line. HEK293/Human CCR5 Stable Cell Line was red line, Negative control HEK293 cells was grey line (QC tested).


Human CCR5, Flag,His Tag (Cat. No. CC5-H52D1) captured on CM5 chip via anti-His antibody can bind Anti-CCR5 antibody (Human IgG1) with an affinity constant of 0.0737 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).


Purified NA/LE Mouse Anti-Human CD195 (Clone: 2D7) (Mouse IgG2a) captured on CM5 chip via anti-mouse antibodies surface can bind Human CCR5, Flag,His Tag (Cat. No. CC5-H52D1) with an affinity constant of 7.51 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).

Synonym Name



Receptor for a number of inflammatory CC-chemokines including CCL3/MIP-1-alpha, CCL4/MIP-1-beta and RANTES and subsequently transduces a signal by increasing the intracellular calcium ion level. May play a role in the control of granulocytic lineage proliferation or differentiation.5 Publications (Microbial infection) Acts as a coreceptor (CD4 being the primary receptor) of human immunodeficiency virus-1/HIV-1.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Maraviroc MVC; UK-427857 Approved Viiv Healthcare Celsentri, Selzentry United States HIV Infections Viiv Healthcare Co 2007-08-06 HIV Infections; Acquired Immunodeficiency Syndrome; Hematologic Neoplasms; Hematopoietic stem cell transplantation (HSCT); Hypertriglyceridemia; Arthritis, Rheumatoid; Graft vs Host Disease; Coronavirus Disease 2019 (COVID-19); Kidney Diseases; Stroke; AIDS Dementia Complex; Cardiovascular Diseases; Inflammation; HIV Seropositivity; Sarcoma, Kaposi Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Vicriviroc SCH-D; MK-4176; SCH-417; Sch-417690 Phase 2 Clinical Merck & Co Inc HIV Infections; Acquired Immunodeficiency Syndrome; Colorectal Neoplasms Details
Cenicriviroc mesylate CCR5/CCR2 antagonist; TBR-652; CVC; TAK-652 Phase 3 Clinical Tobira Therapeutics Inc, Takeda Pharmaceutical Co Ltd HIV Infections; Prediabetic State; Acquired Immunodeficiency Syndrome; Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Liver Cirrhosis; Coronavirus Disease 2019 (COVID-19); AIDS Dementia Complex; Cholangitis, Sclerosing; Hepatic Insufficiency; Obesity; Cognition Disorders Details
Thioraviroc Phase 1 Clinical Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences HIV Infections Details
Leronlimab PRO-140; PA-14; HuPRO-140 Phase 3 Clinical Cytodyn Inc HIV Infections; Solid tumours; Non-alcoholic Fatty Liver Disease; Triple Negative Breast Neoplasms; Graft vs Host Disease; Coronavirus Disease 2019 (COVID-19); Colorectal Neoplasms; HIV Seropositivity Details
OB-002H OB-002; 5P12-RANTES Phase 1 Clinical Scope International Ag, Orion Biotechnology Polska Sp Zoo HIV Infections; Stomach Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Breast Neoplasms; Colorectal Neoplasms; Neoplasm Metastasis Details
BMS-687681 BMS-687681 Phase 1 Clinical Bristol-Myers Squibb Company Neoplasms Details
AGT 103-T AGT 103-T Phase 1 Clinical American Gene Technologies International Inc HIV Infections Details
Cenicriviroc mesylate/Tropifexor LJC-242 Phase 2 Clinical Novartis Pharma Ag Non-alcoholic Fatty Liver Disease Details
SB-728-HSC SB-728-HSC; SB-728-HSPC; SB-728mR-HSPC Phase 1 Clinical Sangamo Biosciences HIV Infections; HIV Seropositivity Details
BMS-813160 BMS-813160 Phase 2 Clinical Bristol-Myers Squibb Company Pancreatic Neoplasms; Colorectal Neoplasms; Hyperplasia; Diabetic Nephropathies; Carcinoma, Pancreatic Ductal; Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
SB-728-T SB-728mR-T; SB-728-T Phase 2 Clinical Sangamo Biosciences HIV Infections Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
Lichtstrasse 35,4056 Basel, Switzerland

Nachricht schicken